Citations

Clear

16280 citation(s) found for "Yu, David".

Universal tau PET scale (Uniτ) – The HEAD Study
Amaral, Lívia , Tudorascu, Dana , Lopresti, Brian J. , Jagust, William J. , Lowe, Val J. , Soleimani‐Meigooni, David N. , Oh, Hwamee , Povala, Guilherme , Bauer‐Negrini, Guilherme , Bellaver, Bruna , Lussier, Firoza Zubeida , Ferreira, Pâmela C.L. , Zatt, Bruno , Klunk, William E. , Pascual, Belén , Gordon, Brian A. , Rosa-Neto, Pedro , Pascoal, Tharick Ali

Mayo Clinic

Alzheimer's & Dementia | January 9, 2025 | Volume: 20 | Issue: S2 | Pages: No page available

10.1002/alz.089555 Get It

Abstract Background The HEAD study aims to collect a large dataset of multiple tau‐PET tracers to provide robust anchor values for tau‐PET harmonization. Here, we tested the hypothesis that anchoring two tau tracer uptake values using head‐to‐head measurements has the potential to generate an accurate universal tau‐PET scale, named Uniτ(tau). Methods We assessed 200 individuals across the aging and AD spectrum (Training: HEAD data freeze 2.0, n=185; Testing: UPitt dataset (Gogola et al.), n=15) with [ 18 F]Flortaucipir and [ 18 F]MK‐6240 tau‐PET. SUVRs were processed to a common 8mm FWHM, with inferior cerebellar gray matter as the reference region (Pascoal et al.). Uniτ explored two anchoring/harmonization methods. First, we examined within‐tracer anchoring by creating anchor values based on the mean SUVR of Youngs (<25 years) and 95th percentile voxels from cognitively impaired individuals. Second, we explored within‐ plus between‐tracer anchoring, employing linear (e.g., piecewise) and non‐linear regressions. To address the inherent problem of discontinuity of piecewise transformations, we implemented two smoothing methods at the inflection point between equations, transforming them into a continuous function. Results Uniτ scale anchoring within‐tracer resulted in similar estimates for high values, but less accurate in the lower range (Figure 1,2). Anchoring within‐ plus between‐tracer improved estimate consistency, with the piecewise transformation generating the best results. The piecewise smoothing equation yielded estimates comparable to those obtained from the piecewise method without smoothing. This allowed for the use of a single formula. In addition, this leads to more robust results when the goal is to study longitudinal changes in the scale (data not shown). UPitt testing dataset showed similar results to the training set (Figure 3). Conclusion Our preliminary findings suggest that anchoring tau‐PET values both within and between tracers has the potential to harmonize tau‐PET tracers, while preserving their characteristics. Currently, piecewise smoothing is the preferred method for Uniτ, but we are continuously fine‐tuning scale parameters as we acquire more data. The final scale parameters will be determined based on extensive training and testing data from multiple tracers. This cautious methodology holds the promise of delivering reliable, robust, and reproducible results, ensuring safe usage of the scale in clinical trials, and potentially paving the way for future use in clinical practice.
Exploring a weighted composite score for harmonization of 18F‐MK6240 and 18F‐ Flortaucipir: linearity and correlations with cognitive measures in a head‐to‐head tau PET dataset – The HEAD Study
Finn, Quentin, Franco, Andrea , Vo, Tam , Amaral, Lívia , Lowe, Val J. , Oh, Hwamee , Soleimani‐Meigooni, David N. , Baker, Suzanne L. , Masdeu, Joseph C. , Povala, Guilherme , Bauer‐Negrini, Guilherme , Franco, Andrea, Vo, Tam, Lussier, Firoza Zubeida , Gordon, Brian A. , Klunk, William E. , Rosa-Neto, Pedro , Masdeu, Joseph C , Pascoal, Tharick Ali , Pascual, Belén

Mayo Clinic

Alzheimer's & Dementia | January 9, 2025 | Volume: 20 | Issue: S2 | Pages: No page available

10.1002/alz.089551 Get It

AbstractBackgroundHarmonization of the two most commonly used Tau PET tracers, 18F‐Flortaucipir and 18F‐MK6240 has proven to be complex. Unlike the centiloid scale for amyloid tracers, Tau PET SUVRs of the two tracers are not linearly comparable and vary markedly in dynamic range and sensitivity.MethodTau PET SUVRs for Braak stage (1‐6) in 18F‐MK6240 and 18F‐Flortaucipir were obtained from the Longitudinal multicenter head‐to‐head harmonization of tau‐PET tracers (HEAD) project. For training, we used 13 amyloid confirmed AD, 24 amyloid confirmed MCI and 66 amyloid negative controls. To assess linearity and correlations with neuropsychological tests, we included the training data as well as 74 subjects of unknown or inconsistent amyloid status. Two methods of generating outcome measures were used. (1) As a stand‐in for Tau load, similar to the centiloid scale, a score of 100, 50 or 0 was given to participants of the training set by multiplying CDR score by 100. Hierarchical and ridge regression were performed for each tracer using PET‐Braak SUVRs as predictive variables. Regression coefficients were used to calculate an outcome measure for all participants. (2) Principal component analysis (PCA) was applied for each tracer to the vectors of PET‐Braak regional SUVR of the training subset. Projections along the principal axis were calculated for both modalitiesResultHierarchical, ridge regression and PCA all yielded composite measures with good linear dependence between the two tracers (r2 for hierarchical, ridge and PCA were 0.84, 0.80, 0.80, respectively). Regions remaining in the hierarchical regression analyses varied between tracers: predictive regions for 18F‐MK6240 were PET‐Braak 1, 4 and 5, while 18F‐Flortaucipir used only PET‐Braak 1 and 5. Composite measures correlated well with MMSE and total MOCA score with all composite measures r < ‐0.61.ConclusionWhile both tracers may have different sensitivities to regional Tau distributions and disease stages, weighting multiple regions differently for each tracer gives a composite score linearly comparable across tracers that correlates with neuropsychological measures. This study is limited by the low total tau load and impairment level of all participants and would benefit from the inclusion of patients with more disease progression.
Tau deposition is associated with neurite abnormalities in white matter tracts and cortical grey matter regions in dementia with Lewy bodies
Przybelski, Scott A. , Lesnick, Timothy G. , Raghavan, Sheelakumari , Jain, Manoj , Miyagawa, Toji , Forsberg, Leah K. , Fields, Julie A. , Savica, Rodolfo , Graff‐Radford, Jonathan , Graff‐Radford, Neill R., Petersen, Ronald C. , Lowe, Val J. , Mak, Elijah , Reid, Robert I. , Schwarz, Christopher G. , Senjem, Matthew L. , Vemuri, Prashanthi , Jack, Clifford R. , Min, Hoon-Ki Paul , Jones, David T. , Botha, Hugo , Louis, Erik K. St. , Knopman, David S. , Ramanan, Vijay K. , Dickson, Dennis W. , Graff‐Radford, Neill R. , Ferman, Tanis J. , Boeve, Bradley F. , O'Brien, John Tiernan , Kantarci, Kejal

Mayo Clinic

Alzheimer's & Dementia | January 9, 2025 | Volume: 20 | Issue: S2 | Pages: No page available

10.1002/alz.089309 Get It

AbstractBackgroundDementia with Lewy bodies (DLB) frequently co‐occurs with Alzheimer’s disease (AD) pathologies, exacerbating disease progression. Biophysical models of diffusion imaging data, such as Neurite Orientation Dispersion and Density Imaging (NODDI), may reveal novel insights into the neurobiological substrates of AD on cortical and white matter microstructural injury.MethodA cohort of 57 DLB patients on the DLB spectrum (33 clinically probable DLB and 14 prodromal DLB) and 57 cognitively unimpaired (CU) controls underwent NODDI and PET imaging with [18F]‐Flortaucipir and [11C]‐PiB (Table 1). NODDI parameters were derived from white matter tracts and grey matter regions using the JHU “Eve” and Mayo Clinic Adult Lifespan Template atlases, respectively. Conditional logistic models were used to compare these parameters between the two groups, accounting for the 1:1 matching on age and sex. The associations of tau and amyloid‐β with NODDI parameters across the white matter tracts were examined with linear regressions. A region‐by‐region approach was adopted to evaluate the relationships of tau and amyloid‐β with grey matter NODDI, adjusting for age, APOE, and local grey matter volumes.ResultDLB spectrum patients exhibited extensive white matter abnormalities relative to CU, including lower fractional anisotropy, higher mean diffusivity (MD), and lower tissue‐weighted neurite density (tNDI). In grey matter, these deficits were paralleled with higher MD and lower tNDI and ODI, primarily in the temporoparietal and posterior cortices. Regression models revealed significant associations of elevated [18F]‐Flortaucipir uptake with deficits in temporal and limbic white matter tracts and a temporal‐lobe pattern of higher MD and lower tNDI in the cortex (Figure 1). No associations were observed with [11C]‐PiB in the DLB spectrum.ConclusionThese findings demonstrated an in vivo relationship between tau deposition and neurite deficits that spatially aligned with the canonical AD “cortical signature” of neurodegeneration in both white matter tracts and grey matter regions in DLB. Our study underscores the detrimental impact of AD pathology in DLB and provides a rationale for further investigations into the underlying mechanisms of AD in DLB. Future longitudinal studies tracking the progression of these changes could inform therapeutic strategies for DLB in the presence of AD pathologies
Comparison of olfactory and cognitive measures to neuroimaging biomarkers in the prediction of cognitive decline and dementia in the MCSA cohort
Devanand, Davangere P. , Vassilaki, Maria , Motter, Jeffrey N. , Lee, Seonjoo , Knopman, David S. , Luchsinger, Jose Alejandro

Mayo Clinic

Alzheimer's & Dementia | January 9, 2025 | Volume: 20 | Issue: S2 | Pages: No page available

10.1002/alz.084722 Get It

AbstractBackgroundInexpensive, non‐invasive tests may improve the identification of persons at increased risk for cognitive decline and dementia. We compared impairment in odor identification and global cognition with neuro‐imaging biomarkers to predict cognitive decline and dementia in the population‐based Mayo Clinic Study of Aging (MCSA).MethodAt the 2008 assessment, 647 participants who were ≥ 55 years old with at least one follow‐up had the following procedures: modified Blessed Information‐Memory‐Concentration Test (BIMCT), 12‐item Brief Smell Identification Test (BSIT), brain magnetic resonance imaging (MRI), and Positron Emission Tomography (PET) amyloid imaging with 11C‐Pittsburgh compound B (11C‐PiB). A subsample (n=556) also had 18F‐fluorodeoxyglucose (18F‐FDG) PET scans. The utility of these baseline measures to predict cognitive decline (cognitively unimpaired to mild cognitive impairment [MCI] or dementia, or MCI to dementia) was examined during follow‐up (mean 8.1 SD 3.4 years). Transition to dementia was a secondary outcome.ResultAmong 647 participants without dementia (mean age 74.0 SD 8.1 years; 54.4% male) at baseline, 102 participants manifested cognitive decline and 34 participants transitioned to dementia. In Cox regression survival analyses for cognitive decline, PiB PET showed the strongest predictive utility (hazard ratio HR 5.05, 95% CI = 3.32‐7.69, p<.001). Impaired BSIT (HR 3.46, 95% CI = 2.34‐5.11, p<.001), impaired BIMCT (HR 3.63, 95% CI 2.46‐5.36, p<.001), MRI and FDG measures were also significant predictors. After adjusting for age, sex and education, these predictors remained significant with attenuated effects (PiB HR 3.89, 95% CI 2.54‐5.95, p<.001; BSIT HR 2.77, 95% CI 1.85‐4.14, p<.001; BIMCT HR 3.3, 95% CI 2.21‐4.95, p<.001). After adding these demographic variables in the model, the combination of BSIT and BIMCT showed strong predictive utility (C‐index=0.85), similar to PiB PET (C‐index=0.84). Combining all predictors showed a C‐index of 0.89. These measures showed similar but stronger results for dementia transition.ConclusionTests of global cognition and odor identification provide a brief, non‐invasive, inexpensive method comparable to PET amyloid imaging for identifying community‐dwelling persons likely to decline cognitively or transition to dementia. Other potential uses for this combination include identification of persons likely to benefit from disease‐modifying medications and determination of eligibility for prevention trials.
Amyloid‐PET in patients with a clinical diagnosis of sporadic early‐ versus late‐onset AD: comparison of the LEADS and ADNI cohorts
Zhang, Jiaxiuxiu, Soleimani‐Meigooni, David N. , Zeltzer, Ehud , Windon, Charles , Hammers, Dustin B. , Eloyan, Ani , Landau, Susan, Touroutoglou, Alexandra , Apostolova, Liana G. , Windon, Charles , Lagarde, Julien , Maiti, Piyush , Schonhaut, Daniel R. , Zhang, Jiaxiuxiu, Raya, Maison Abu , Vrillon, Agathe , Hammers, Dustin B , Dage, Jeffrey L. , Nudelman, Kelly , Koeppe, Robert A. , Carrillo, María C. , Vemuri, Prashanthi , Dickerson, Bradford Clark , Rabinovici, Gil D. , Joie, Renaud La

Mayo Clinic

Alzheimer's & Dementia | January 9, 2025 | Volume: 20 | Issue: S2 | Pages: No page available

10.1002/alz.092903 Get It

AbstractBackgroundLarge‐scale studies comparing sporadic early‐onset AD (EOAD, age<65) and late‐onset AD (LOAD, age≥65) are lacking. We compared amyloid‐PET outcomes (positivity rate and amyloid burden) between patients clinically diagnosed with sporadic EOAD vs LOAD, leveraging data from the Longitudinal Early‐Onset AD Study (LEADS) and the Alzheimer’s Disease Neuroimaging Initiative 3 (ADNI3).Method731 patients meeting the 2011 NIA‐AA criteria for AD dementia or MCI were included (505 early‐onset from LEADS, 226 late‐onset from ADNI3, Table 1). All participants underwent amyloid‐PET with [18F]Florbetaben or [18F]Florbetapir. Amyloid positivity was centrally determined by a process involving a visual read by a trained expert and PET‐only quantification; in case of a discrepancy, a read from an independent physician acted as a tiebreaker. Logistic regressions in each cohort examined relations between amyloid positivity and age, sex, MMSE and APOE4 genotype. Amyloid burden was independently quantified in Centiloids using an MRI‐based pipeline. Mean Centiloids in LEADS and ADNI were compared with two‐way ANOVA, for visually positive and visually negative scans.ResultAmyloid positivity rate was higher in LEADS (76%) than ADNI (64%, p<0.001, Figure 1A). Lower MMSE and APOE4 genotype increased odds of amyloid positivity in both cohorts, although the APOE4 effect was stronger in ADNI than LEADS (OR=10.1 versus 2.4, p=0.007, Table 2). Amyloid positivity was more common in females across cohorts, but this effect was only statistically significant in LEADS (Table 2). Centiloids were bimodally distributed in both cohorts, although the separation between positive and negative scans was more prominent in LEADS (Figure 1B). Visually positive scans had significantly higher Centiloids in LEADS than in ADNI, whereas no cohort difference was observed for visually negative scans (Figure 1C). Sensitivity analyses showed that this effect was driven by patients with MCI (CDR≤0.5; Figure 1D‐E).ConclusionThe lower amyloid positivity rate in ADNI might be due to AD‐mimicking pathologies being more common at an older age. The higher amyloid burden in early‐onset, amyloid‐positive patients could reflect younger patients being diagnosed later in the disease course compared to typical, late‐onset patients. Alternatively, younger patients might tolerate higher neuropathology burden due to higher brain reserve or fewer co‐pathologies.
Voxel‐wise comparison of [18F]MK6240 and [18F]Flortaucipir for the diagnosis of individuals across the Alzheimer’s disease spectrum – the HEAD study
Amaral, Lívia , Lowe, Val J. , Soleimani‐Meigooni, David N. , Oh, Hwamee , Tudorascu, Dana , Jagust, William J. , Baker, Suzanne L. , Bellaver, Bruna , Povala, Guilherme , Bauer‐Negrini, Guilherme , Lussier, Firoza Zubeida , Ferreira, Pâmela C.L. , Klunk, William E. , Pascual, Belén , Gordon, Brian A. , Rosa-Neto, Pedro , Pascoal, Tharick Ali

Mayo Clinic

Alzheimer's & Dementia | January 9, 2025 | Volume: 20 | Issue: S2 | Pages: No page available

10.1002/alz.092862 Get It

AbstractBackgroundIn vivo studies using the tau PET tracers have shown high performance for the diagnosis of Alzheimer’s disease dementia and patterns of tracer uptake that resemble those observed in post‐mortem studies. However, tau tracers present distinct patterns of binding that might influence their performance in detecting AD pathology. In a head‐to‐head study, we investigated the performance of [18F]MK6240 and [18F]Flortaucipir for the diagnosis of AD.MethodWe assessed 132 individuals from the HEAD study (58 CU Aβ‐, 15 CU Aβ+, 14 MCI Aβ‐, 32 MCI Aβ+ and 13 AD dementia) with Aβ‐PET, [18F]MK6240 and [18F]Flortaucipir. Voxel‐wise receiver operating characteristic curves (ROC) of the two tau tracers were used to contrast groups provided the area under the curve (AUC) for disease diagnosis or biomarkers positivity.ResultThe brain maps showed numerically higher and more spread AUC for [18F]Flortaucipir to discriminate CU Aβ‐ from CU Aβ+ (Figure 1A). The difference between tracers’ AUC was greater in Braaks IV and V (Figure 2A), both regions that are not expected to have tau accumulation in CU Aβ+ individuals, reflecting a potential off‐target binding for [18F]Flortaucipir. To differentiate CU Aβ‐ from MCI Aβ+ individuals, [18F]MK6240 presented a numerically higher AUC than [18F]Flortaucipir in Braak I and II and similar AUC in other Braak regions (Figure 1B, 2B). We observed a high performance of [18F]MK6240 and [18F]Flortaucipir in differentiating AD dementia from CU Aβ‐ individuals. However, [18F]MK6240 exhibits a higher AUC than [18F]Flortaucipir in all Braak regions, especially Braak V‐VI (Figure 1C, 2C). Finally, [18F]MK6240 presented higher AUC in all Braak regions to discriminate MCI Aβ‐ from MCI Aβ+ individuals (Figure 1D, 2D).ConclusionOur results indicate that [18F]MK6240 and [18F]Flortaucipir present high accuracy to discriminate AD from CU Aβ‐ individuals. However, [18F]MK6240 presents higher AUC to discriminate AD and MCI Aβ+ from CU Aβ‐ individuals than [18F]Flortaucipir. Together, our head‐to‐head study sheds light on the distinct patterns of binding for Tau‐PET tracers.
CU PET Aβ and Tau Positive Individuals Show Impairment in MoCA Delayed Recall
Felix, Cynthia, Kollasserry, Felix Joy, Snitz, Beth E. , Rebok, George W. , Tudorascu, Dana , Oliveira, Markley, Lemaire, Peter Charles , Abbas, Sarah , Amaral, Lívia , Lowe, Val J. , Oh, Hwamee , Soleimani‐Meigooni, David N. , Jagust, William J., Baker, Suzanne L. , Ferreira, Pâmela C.L. , Rodrigues, Matheus Scarpatto , Povala, Guilherme , Bauer‐Negrini, Guilherme , Medeiros, Marina Scop , Soares, Carolina , Aguzzoli, Cristiano Schaffer , Bellaver, Bruna , Lussier, Firoza Zubeida , Pascual, Belén , Gordon, Brian A. , Klunk, William E. , Rosa-Neto, Pedro , Pascoal, Tharick Ali

Mayo Clinic

Alzheimer's & Dementia | January 9, 2025 | Volume: 20 | Issue: S2 | Pages: No page available

10.1002/alz.092683 Get It

AbstractBackgroundIdentification of cognitively unimpaired (CU) individuals who may progress to mild cognitive impairment (MCI), is a pressing issue in the Alzheimer’s disease (AD) field, since therapeutic interventions may be more effective in the absence of cognitive impairment and neurodegeneration. CU individuals positive for amyloid and tau PET are very likely in the AD pathway. In out‐patient cognitive screening, we use rapid and simple tests such as The Montreal Cognitive Assessment (MoCA) ‐ a composite of executive, visuospatial, naming, attention, language, abstraction, delayed recall, and orientation performances. We hypothesize that sub‐categorizing the CU group based on the presence of amyloid (A) and tau (T) pathologies, as measured by PET, can reveal subtle cognitive deficits, even in a clinical test with low sensitivity such as MoCA.MethodWe included 88 CU [defined as CDR global score of 0] older adults with available head‐to‐head MK6240 tau‐PET and Flortaucipir tracers from the ongoing HEAD multi‐site observational study. They also underwent Amyloid PET imaging using PiB or NAV4694. MoCA testing was done around the imaging time. To increase similarity with clinical practice, Amyloid and Tau PET positivity was defined using visual reads. Based on tracer uptake status, we categorized the individuals into A‐T‐, A‐T+, A+T‐ and A‐T‐ groups. Unpaired t‐test and one‐way ANOVA were used to test for significant differences between groups.Result2‐tailed p‐values were significant between the A‐T‐ group and the A+T+ group for MoCA total score [p: 0.0025 and p: 0.0025]. When we stratified MoCA in the different cognitive domains, we found that the results were driven by MoCA (memory) Delayed Recall score [p: 0.0007 and p: 0.0162]. A‐T+ vs A+T+ was also significant [p: 0.0099] for MoCA Delayed Recall. Both tau tracers (MK6240 and Flortaucipir) showed similar performance for determining T+ and identifying cognitive decline.ConclusionMoCA, a simple and commonly administered in‐office neuropsychological test, can detect subtle cognitive dysfunction in CU older adults who are Aβ and tau positive (A+/T+). These CU A+/T+ individuals are likely on the path to developing AD dementia.
Amyloid PET Detects the Deposition of Brain Aβ Earlier than CSF Fluid Biomarkers
Lowe, Val J. , Mester, Carly , Lee, Jeyeon , Ghatamaneni, Sujala, Campbell, Michelle R. , Graff‐Radford, Jonathan , Kantarci, Kejal, Knopman, David S., Petersen, Ronald C. , Lundt, Emily S. , Algeciras‐Schimnich, Alicia , Nguyen, Aivi T. , Min, Hoon-Ki Paul , Murray, Melissa E. , Senjem, Matthew L. , Schwarz, Christopher G. , Kantarci, Kejal , Boeve, Bradley F. , Vemuri, Prashanthi , Jones, David T. , Jack, Clifford R. , Mielke, Michelle M.

Mayo Clinic

Alzheimer's & Dementia | January 9, 2025 | Volume: 20 | Issue: S2 | Pages: No page available

10.1002/alz.092471 Get It

AbstractBackgroundUnderstanding the relationship between AβPET and AβCSF biomarkers will define their potential utility in Aβ treatment. Few longitudinal or neuropathological comparisons have been reported. We assessed the relationship of AβPET and AβCSF biomarkers in a large community cohort.MethodParticipants 50+ years with coincident AβPET and AβCSF biomarkers (pTau181/Aβ42, n=505, and Aβ42/40, n=54) were included. Of these participants, a subgroup was identified that had neuropathology data (n=47) of which many had longitudinal AβPET and CSF testing. The relationships of AβPET and CSF biomarkers were assessed cross‐sectionally in all participants and longitudinally in those with autopsy data. Analyses were performed using AβPET Meta‐ROI and AβPET early‐Aβ‐deposition ROIs (ROIs with early Aβ deposition: fusiform, angular, inferior temporal, middle temporal, middle occipital, and calcarine).ResultIn biomarker tests performed at the same time, more participants were AβPET+ and CSF‐ than AβPET‐ and CSF+ using Meta‐ROI AβPET. This discordance occurred more frequently when using early‐Aβ‐deposition regions (Figure 1). Of 47 participants with autopsy data, 35 had Thal stage ≥1. The sensitivity for earliest detection of cortical Aβ neuropathology by AβPET was 89% (31/35) and by CSF was 66%, (23/35). Eight of these 35 had positive AβPET findings and negative coincident CSF tests at the first time tested. Of these, 5/8 were Meta‐ROI and early AβPET ROI positive. The other 3/8 were only positive on early‐Aβ AβPET ROIs. Four of the 8 with negative CSF and positive AβPET had subsequent testing and 2/4 became positive on CSF tests after 1.5 years while 2/4 continued to be negative on subsequent testing.ConclusionAβPET is more sensitive for detection of early cortical Aβ deposition than CSF biomarkers in cross‐sectional or autopsy data. While the assessment of AβPET by standard Meta‐ROI AβPET methods showed cortical Aβ deposition occurring when not indicated by CSF biomarkers, AβPET ROIs for early Aβ deposition detected additional participants that were AβPET positive and AβCSF negative. These findings have implications for detecting early Aβ neuropathology among CU participants in Aβ prevention trials when robust detection is needed. Further work is needed to compare Aβ plasma biomarkers and AβPET using these methods.
Central and Peripheral Biochemical Changes in Alzheimer's Disease: Insights from the Alzheimer Disease Metabolomics Consortium
Allen, Mariet , Wörheide, Maria A. , Blach, Colette , Seyfried, Nicholas T. , Ertekin‐Taner, Nilüfer , Krumsiek, Jan, Batra, Richa , Arnold, Matthias , Wang, Xue , Levey, Allan I. , Bennett, David A. , Kastenmüller, Gabi , Kaddurah‐Daouk, Rima

Mayo Clinic

Alzheimer's & Dementia | January 9, 2025 | Volume: 20 | Issue: S2 | Pages: No page available

10.1002/alz.092421 Get It

AbstractBackgroundOur Alzheimer Disease Metabolomics Consortium (ADMC), part of the Accelerating Medicines Partnership for AD (AMP‐AD) and in partnership with AD Neuroimaging Initiative (ADNI), applied state‐of‐the‐art metabolomics and lipidomics technologies combined with genomic and imaging data to map metabolic failures across the trajectory of the disease. Our studies confirmed that peripheral metabolic changes influenced by the exposome inform about cognitive changes, brain imaging changes, and ATN markers for disease confirming that peripheral and central changes are connected, in part through the metabolome.MethodsTo map the biochemical changes in AD, we used various targeted and untargeted metabolic platforms to profile ∼800 postmortem brain tissue, and ∼ 5000 blood samples.ResultsRecently, we built a comprehensive reference map of extensive AD‐related metabolic changes in brain, spanning multiple AD‐related traits, including neuropathological b‐amyloid and tau tangle burden, as well as late‐life cognitive performance. Using this resource, we extracted novel metabolic including bioenergetic pathways, cholesterol metabolism, neuroinflammation, broad impairment of osmoregulation, an imbalance between excitatory/inhibitory neurotransmitter ratios and identification of tau load as a potential driver of metabolic dysfunction in the AD brain, with minimal contributions from b‐amyloid load. As AD and progressive supranuclear palsy (PSP) share the pathological feature of tauopathy and metabolic alterations, we compared their metabolomic profiles to identify shared biological pathways that could be targeted for therapeutic interventions. Our findings indicate that both diseases display oxidative stress, mitochondrial dysfunction, and tau‐induced polyamine stress response.ConclusionOverall, through our studies, (1) We identified biochemical processes altered in AD, with findings supported across both metabolomic and proteomic data, indicating multimodal deregulation. (2) Our research pinpointed widespread AD‐related biochemical changes across various brain regions with differing levels of neuropathology. While there are many overlapping changes across the brain regions, each region also has its distinct metabolic alterations. (3) We identified biochemical processes disrupted by AD, with parallel findings in other neurodegenerative diseases, hinting at broader implications in neurodegenerative research. Currently, we are working on mapping widespread connections of the brain metabolome with various determinants of AD namely genome, gut microbiome, exposome, and linking with peripheral metabolic alterations in AD.
Comparing de‐facing software MiDeFace and mri_reface according to privacy protection and effects on downstream measurements
Prakaashana, Carl M., Gunter, Jeffrey L. , Graff‐Radford, Jonathan, Petersen, Ronald C. , Initiative, The Alzheimer's Disease Neuroimaging, Schwarz, Christopher G. , Kremers, Walter K. , Senjem, Matthew L. , Vemuri, Prashanthi , Kantarci, Kejal , Graff‐Radford, Jonathan , Knopman, David S. , Jack, Clifford R. , Initiative, The Alzheimer's Disease Neuroimaging

Mayo Clinic

Alzheimer's & Dementia | January 9, 2025 | Volume: 20 | Issue: S2 | Pages: No page available

10.1002/alz.091376 Get It

AbstractBackgroundSeveral programs are available for automatically “de‐facing” brain images. These are designed to prevent the potential use of face imagery to re‐identify research participants. Previous works have compared available software and mri_reface is frequently among the top methods. The “Minimally Invasive DeFacing of MRI images” (MiDeFace) program was more recently added to FreeSurfer, but minimal validation of MiDeFace has been published.MethodWe ran mri_reface 0.3.3 and MiDeFace 7.3.2 on two datasets: A) 207 participants with face photographs and 3D T1‐weighted and 3D T2‐weighted‐FLAIR MRI from the Mayo Clinic Study of Aging (all unimpaired, Siemens); and B) 300 participants from ADNI3 with 3D T1‐weighted MRI (50 unimpaired + 50 with clinical AD, from each of 3 vendors). For dataset A, we tested the rate at which Microsoft Azure face recognition matched each participant’s photographs with the correct MRI, comparing unmodified images, those from mri_reface, and those from MiDeFace. For dataset B, we compared measured regional brain volume and cortical thickness from original vs. de‐faced images with SPM12, FreeSurfer 7.4.1, and the FSL‐UK Biobank pipeline. For both datasets, images were visually rated to assess removal of the face and retention of brain tissue.ResultAutomated face recognition match rates were lower with mri_reface (17/207 8.2%) than with MiDeFace (24/207 11.6%), indicating stronger identity protection with mri_reface, but both were greatly reduced vs. unmodified images (203/207 98.1%). Example images with both programs are shown in Figure 1. From visual ratings (Table 1), rates of complete success (modification of the entire face while retaining the entire brain) were much higher with mri_reface, but the great majority of failures from MiDeFace were subtle and occurred in relatively less recognizable face regions. The effects of both programs on downstream imaging measurements (Figure 2) were small and very comparable, but MiDeFace was favored mildly for SPM12 and for FSL, while mri_reface was more favored for FreeSurfer.ConclusionAltogether, mri_reface more reliably removed the complete face, leading to smaller rates of potential re‐identification (8.2% vs 11.6%). Effects on downstream image measurements were small and comparable with both methods.